Drug Update · Infectious Disease

Ciprofloxacin Guidance for Salmonella Infections and Resistance Considerations

September 06, 2026

Infectious diarrhea dosing

500 mg every 12 hours for 5 to 7 days [1]

Typhoid fever dosing

500 mg every 12 hours for 10 days [1]

ƒAUC(0-24)/MIC (DCS vs CS)

41.3 ± 18.8 vs 585.4 ± 219 [8]

Toxic exposure risk with dose escalation

Conceivably toxic levels in 50% of patients if ciprofloxacin dose increased to reach targets [8]

Clinical Perspective

For clinicians caring for patients with suspected Salmonella-associated enteric infections, ciprofloxacin is a labeled oral option for infectious diarrhea and for typhoid fever in adults per product labeling ^[1]^[5]. The labeling advises performing appropriate culture and susceptibility testing before treatment when feasible and notes that empiric therapy may be initiated while awaiting results, with modification when results become available ^[1]^[2]^[3]. Published pharmacokinetic/pharmacodynamic data indicate that decreased ciprofloxacin susceptibility in Salmonella Typhi can compromise treatment efficacy and that simply increasing ciprofloxacin dose may produce toxic exposures in a substantial fraction of patients ^[4].

Dr. Simran Kohli, MBBS, MD (General Medicine), DM (Infectious Diseases) · Infectious Diseases

This drug update summarizes published prescribing information and recent published data relevant to ciprofloxacin use for Salmonella-associated infections. Ciprofloxacin is a fluoroquinolone antibacterial with labeled indications that include infectious diarrhea and typhoid fever; dosing and safety details are described in product labeling and pharmacokinetic/pharmacodynamic analyses cited below ^[1]^[5]^[4].

Clinical Context

Ciprofloxacin is a fluoroquinolone antibacterial referenced in current U.S. prescribing highlights and labeling as an agent indicated for a range of infections, including infectious diarrhea and typhoid fever (enteric fever) caused by Salmonella typhi ^[1]^[2]^[3]^[5]. Multiple marketed ciprofloxacin tablet products appear in DailyMed highlights (examples: Denton Pharma DBA Northwind Pharmaceuticals, NuCare Pharmaceuticals, Medsource Pharmaceuticals) where the product is described as an oral fluoroquinolone antibacterial with initial U.S. approval noted in labeling ^[1]^[2]^[3]. The FDA label for ciprofloxacin products also lists ophthalmic formulations with separate dosing guidance ^[5]. The labeling emphasizes limiting ciprofloxacin use to infections proven or strongly suspected to be bacterial to reduce development of resistance ^[1]^[2]^[3].

Key Findings

Ciprofloxacin is labeled for use in infectious diarrhea at a dosing listed as 500 mg every 12 hours for 5 to 7 days and for typhoid fever at 500 mg every 12 hours for 10 days in adults, per product Highlights of Prescribing Information ^[1]^[2]^[3].
Clinicians should consult current prescribing information for full dosing guidance.
A pharmacokinetic and clinical evaluation of decreased ciprofloxacin susceptibility (DCS) in Salmonella enterica serovar Typhi and Paratyphi infections reported that patients with DCS isolates had a mean ƒAUC(0-24)/MIC of 41.3 ± 18.8 compared with 585.4 ± 219 in patients with ciprofloxacin-susceptible isolates; for comparison, mean ƒAUC(0-24)/MIC values were 60.5 ± 28.7 for levofloxacin and 97.9 ± 28.0 for gatifloxacin in this analysis ^[4]. The study authors reported that increasing ciprofloxacin dose to achieve adequate pharmacodynamic targets could lead to conceivably toxic drug levels in 50% of patients treated with ciprofloxacin ^[4].
The same report noted that the emergence of decreased ciprofloxacin susceptibility in Salmonella Typhi/Paratyphi has been associated with failure of empirical therapy in returned travellers and with longer fever clearance times and increased length of hospital stay in affected patients ^[4].

Safety & Tolerability

Ciprofloxacin labeling includes boxed warnings and multiple named adverse reactions and precautions. Fluoroquinolones, including ciprofloxacin, are associated with an increased risk of tendinitis and tendon rupture and may exacerbate muscle weakness in persons with myasthenia gravis; avoidance is advised in patients with known myasthenia gravis ^[1]^[2]^[3]. Other named warnings and precautions include hepatotoxicity, central nervous system effects (including convulsions and increased intracranial pressure), Clostridium difficile-associated diarrhea, peripheral neuropathy, and QT prolongation ^[1]^[2]^[3]. The most common adverse reactions ≥ 1% listed in highlights are nausea, diarrhea, liver function tests abnormal, vomiting, and rash ^[1]^[2]^[3]. Reported interacting drugs in the labeling include theophylline, warfarin, antidiabetic agents, phenytoin, methotrexate, cyclosporine, and multivalent cation-containing products ^[1]^[2]^[3].

Study Design

Prescribing information and product highlights derive from regulatory labeling and approval records for ciprofloxacin products; label effective dates and approval history are provided in FDA product data ^[5] and in DailyMed highlights for specific marketed products ^[1]^[2]^[3]. A retrospective clinical and pharmacokinetic/pharmacodynamic evaluation of decreased ciprofloxacin susceptibility in Salmonella Typhi and Paratyphi covered patients with positive blood cultures from January 2002 to August 2008 and reported clinical outcomes and ƒAUC(0-24)/MIC analyses comparing ciprofloxacin, levofloxacin, and gatifloxacin ^[4]. Further design details and full methods are available in the cited publication ^[4].

FAQ

Q1 What is ciprofloxacin approved for?

Ciprofloxacin is approved as a fluoroquinolone antibacterial for multiple indications in adults and in pediatric populations where indicated. In systemic formulations, labeled adult indications include urinary tract infections, lower respiratory tract infections, skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections (used in combination with metronidazole), infectious diarrhea, and typhoid fever (enteric fever). Ophthalmic ciprofloxacin has labeled indications for corneal ulcers and bacterial conjunctivitis. Clinicians should consult current prescribing information for complete dosing guidance.

Q2 How does ciprofloxacin work?

Ciprofloxacin is described in product labeling as a fluoroquinolone antibacterial agent. Detailed mechanism-of-action text sections are present in full prescribing information, but specific mechanistic statements beyond the drug class designation are not included in the provided source excerpts. Clinicians should consult current prescribing information for complete dosing guidance.

Q3 What is the dose for Salmonella-associated enteric infections?

Product highlights list adult dosing for infectious diarrhea as 500 mg every 12 hours for 5 to 7 days and for typhoid fever as 500 mg every 12 hours for 10 days. Individual product labeling and renal function-based dosing adjustments appear in full prescribing information; dosing for ophthalmic formulations and pediatric indications is different and specified separately in labeling. Clinicians should consult current prescribing information for complete dosing guidance.

Q4 What are the side effects and interactions to watch for?

Labeled important risks for ciprofloxacin include tendinopathy and tendon rupture and exacerbation of myasthenia gravis, with additional warnings for hepatotoxicity, central nervous system effects, Clostridium difficile-associated diarrhea, peripheral neuropathy, and QT prolongation. The most common adverse reactions ≥ 1% listed in highlights include nausea, diarrhea, abnormal liver function tests, vomiting, and rash. Notable drug interactions named in the highlights include theophylline, warfarin, antidiabetic agents, phenytoin, methotrexate, cyclosporine, and multivalent cation-containing products. Clinicians should consult current prescribing information for complete dosing guidance.

Clinicians should consult current prescribing information for complete dosing guidance.

Ciprofloxacin Guidance for Salmonella Infections and Resistance Considerations

Direct Clinical Takeaway & Evidence Summary

Ciprofloxacin Guidance for Salmonella Infections and Resistance Considerations

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Cite & Reference This Monograph

Get weekly clinical updates for Infectious Disease in your inbox.

Related Clinical Updates

FDA Approves Ensitrelvir (XOCOVA) for COVID-19 Post‑Exposure Prophylaxis: 67% Reduction in Confirmed Symptomatic COVID-19 in SCORPIO-PEP

AREXVY Expanded for Adults 18–59 at Increased RSV Risk

FDA Expands AREXVY to Adults 18–59 at Increased RSV Risk

Verified HCP Portal